CORAL SPRINGS, FL, Apr 03, 2014 (Marketwired via COMTEX) -- Nutra Pharma Corp. (otcqb:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel has signed an agreement that creates the MyNyloxin Telemarketing Division (MTD). MTD will begin their telemarketing campaign on April 7 to identify customers for Nyloxin(R) as well as potential Distributors for MyNyloxin.com.
"The MyNyloxin Telemarketing Division will actively find opportunity seekers to purchase and sell the Nyloxin Product line which will also include Nyloxin Pet Pain Away," stated Dalton Johnson, CEO of MyNyloxin.com. "They will begin with approximately 2,000 outbound calls daily with the goal of growing to over 70,000 daily calls by the end of 2014," he continued. "This is a proven mechanism for rapid growth in our industry. Their marketers will provide access to a superior pain relief product that customers need as well as an innovative network marketing program which offers a fair and balanced compensation plan for both the average and ambitious MyNyloxin Independent Entrepreneur," he concluded.
Nyloxin(R) is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin(R) is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin(R) is also offered in an extra strength formula for more advanced, Stage 3, chronic pain. The Company will also make Pet Pain-Away available by the end of the 2nd quarter. Pet Pain-Away is a new product primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in companion animals. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.
"MyNyloxin Distributors have been consistently increasing the public awareness of Nyloxin," said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This new campaign will begin with over 2,000 calls daily to potential Nyloxin customers and potential MyNyloxin Distributors. We believe that this may create significant market penetration and subsequent sales growth over the next several months," he concluded.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin(R) and Nyloxin(R). For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com .
SEC Disclaimer This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The launch of MTD should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov . Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.